Download PDF
Zeitschrift für Phytotherapie 2022; 43(03): 105-111
DOI: 10.1055/a-1883-6090
Forschung

Lavendel bei Angststörungen – Schwerpunkt Lavendelöl

Hans-Peter Volz
1   Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin Schloss Werneck
› Author Affiliations
› Further Information
    Permissions and Reprints

Zusammenfassung

Angststörungen sind als Gruppe betrachtet die häufigsten psychiatrischen Erkrankungen überhaupt, die Ein-Jahres-Prävalenz beträgt 14%. In dem vorliegenden Beitrag werden zunächst die wichtigsten klinischen Charakteristika dieser Erkrankungen vorgestellt und wie zu einer differentialdiagnostischen Einschätzung gelangt werden kann. Die wichtigsten Behandlungsmethoden für diese Störungen sind Psychotherapie und Pharmakotherapie. Bei letzterer Option besitzt das Phytopharmakon Silexan einen besonderen Stellenwert, da dessen Effektivität und Verträglichkeit in einer Reihe von doppelblinden, meist placebokontrollierten Studien im Indikationsbereich subsyndromale Angststörungen und generalisierte Angststörung gezeigt werden konnten; auch Metaanalysen über diese Studien bestätigten diese günstigen Ergebnisse. Zudem liegen Interaktionsstudien und spezielle Studien zur Fahrfähigkeit und zu dem Fehlen von Absetzeffekten vor. Insofern stellt Lavendelöl eine wertvolle Alternative zur Pharmakotherapie der Angststörungen dar.

ABSTRACT

Anxiety disorders are per se the most common psychiatric disorders, with an annual prevalence of 14%. In this article, the most important clinical characteristics of anxiety disorders are presented with emphasis on how to arrive at a differential diagnostic assessment. The main treatment methods for these disorders are psychotherapy and pharmacotherapy. With regard to pharmacotherapy, the lavender oil preparation Silexan has a special place, since its effectiveness and tolerability have been exhibited in a series of double-blind and placebo- controlled studies in the indication area of subsyndromal anxiety disorders as well as generalized anxiety disorder. Meta-analyses of these studies also confirmed these favourable results. Moreover, there are interaction studies and special studies on driving ability and the lack of withdrawal effects. In this respect, lavender oil represents a valuable alternative to the pharmacotherapy of anxiety disorders.

Schlüsselwörter

Angststörungen - Behandlungsmöglichkeiten - Phytotherapie - Lavendelöl - klinische Studien - Metaanalysen - Pharmakologie

Key words

Anxiety disorders - treatment options - phytotherapy - lavender oil - clinical trials - meta-analysis - pharmacology


Publication History

Article published online:
19 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bandelow B, Aden I, Alpers GW. et al. S3-Leitlinie Behandlung von Angststörungen, Version 2 2021; Registernr 051-028 https://www.awmf.org/leitlinien/detail/ll/051-028.html
    PubMed
  • 2 Denner SS. Lavandula angustifolia Miller: English lavender. Holist Nurs Pract 2009; 23: 57-64
    CrossrefPubMedGoogle Scholar
  • 3 Doroshyenko O, Rokitta D, Zadoyan G. et al. Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos 2013; 41: 987-993
    CrossrefPubMedGoogle Scholar
  • 4 Dr. Willmar Schwabe GmbH & Co. KG. Clinical and biometrical study report (2010/1a). A single-centre, randomized, placebo-controlled, double-blind study to assess the tolerability and pharmacokinetics of linalool after repeated daily administration of 160 mg and 320 mg of Silexan WS 1265 for two weeks in healthy male and female subjects. Karlsruhe: Dr. Wilmar-Schwabe GmbH & Co. KG; 2010
    PubMed
  • 5 Dr. Willmar Schwabe GmbH & Co. KG. A stepwise sequential dose-rising phase I study to assess the safety and tolerability of single p.o. doses of 80 to 640 mg Silexan WS 1265 in healthy subjects. Karlsruhe: Dr. Wilmar-Schwabe GmbH & Co. KG; 2010
    PubMed
  • 6 Jacobi F, Hofler M, Strehle J. et al. Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). Nervenarzt 2014; 85: 77-87
    CrossrefPubMedGoogle Scholar
  • 7 Gastpar M, Müller WE, Volz HP. et al. Silexan does not cause withdrawal symptoms even when abruptly discontinued. Int J Psychiatry Clin Pract 2017; 21: 177-180
    CrossrefPubMedGoogle Scholar
  • 8 Heger-Mahn D, Pabst G, Dienel A. et al. No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination. Drugs R D 2014; 14: 265-272
    CrossrefPubMedGoogle Scholar
  • 9 Kalk NJ, Nutt DJ, Lingford-Hughes AR. The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol 2011; 25: 3-16
    CrossrefPubMedGoogle Scholar
  • 10 Kasper S, Gastpar M, Müller WE. et al. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 2010; 25: 277-287
    CrossrefPubMedGoogle Scholar
  • 11 Kasper S, Gastpar M, Müller WE. et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder - a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol 2014; 17: 859-869
    CrossrefPubMedGoogle Scholar
  • 12 Kasper S, Anghelescu I, Dienel A. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 25: 1960-1967
    CrossrefPubMedGoogle Scholar
  • 13 Kasper S, Volz HP, Dienel A, Schläfke S. Efficacy of Silexan in mixed anxiety-depression – A randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2016; 26: 331-340
    CrossrefPubMedGoogle Scholar
  • 14 Kasper S, Müller WE, Volz HP. et al. Silexan in anxiety disorders: Clinical data and pharmacological background. World J Biol Psychiatry 2018; 19: 412-420
    CrossrefPubMedGoogle Scholar
  • 15 Kumar V. Characterization of anxiolytic and neuropharmacological activities of Silexan. Wien Med Wochenschr 2013; 163: 89-94
    CrossrefPubMedGoogle Scholar
  • 16 Möller HJ, Bandelow B, Volz HP. et al. The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 2016; 266: 725-736
    CrossrefPubMedGoogle Scholar
  • 17 Möller HJ, Volz HP, Dienel A. et al. Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci 2019; 269: 183-193
    CrossrefPubMedGoogle Scholar
  • 18 Möller HJ, Volz HP, Seifritz E. et al. Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. J Psychiatr Res 2021; 136: 543-551
    CrossrefPubMedGoogle Scholar
  • 19 Müller WE, Schuwald A, Noeldner M. et al. Pharmakologische Basis des therapeutischen Gebrauchs von Silexan (Lasea®). Psychopharmakotherapie 2015; 22: 3-13
    PubMedGoogle Scholar
  • 20 Müller WE, Sillani G, Schuwald A, Friedland K. Pharmacological basis of the anxiolytic and antidepressant properties of Silexan®, an essential oil from the flowers of lavender. Neurochem Int 2021; 143: 104899
    CrossrefPubMedGoogle Scholar
  • 21 Musazzi L, Racagni G, Popoli M. Stress, glucocorticoids and glutamate release: effects of antidepressant drugs. Neurochem Int 2011; 59: 138-149
    CrossrefPubMedGoogle Scholar
  • 22 Sasannejad P, Saeedi M, Shoeibi A. et al. Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial. Eur Neurol 2012; 67: 288-291
    CrossrefPubMedGoogle Scholar
  • 23 Schuwald AM, Nöldner M, Wilmes T. et al. Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One 2013; 8: e59998
    CrossrefPubMedGoogle Scholar
  • 24 Seifritz E, Möller HJ, Volz HP. et al. No abuse potential of Silexan in healthy recreational drug users: A randomized controlled trial. Int J Neuropsychopharmacol 2021; 24: 171-180
    CrossrefPubMedGoogle Scholar
  • 25 Ströhle A, Gensichen J, Domschke K. Die Diagnose und Behandlung von Angststörungen. Dtsch Arztebl 2018; 115: 611-620
    PubMedGoogle Scholar
  • 26 von Känel R, Kasper S, Bondolfi G. et al. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta-analysis. Brain Behav 2021; 11: e01997
    CrossrefPubMedGoogle Scholar
  • 27 Volz HP, Stieglitz RD. Angststörungen – Diagnostik, Psycho- und Pharmakotherapie. DNP – Der Neurologe & Psychiater 2019; 20: 92-101
    CrossrefPubMedGoogle Scholar
  • 28 Volz HP, Saliger J, Kasper S. et al. Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. Int J Psychiatry Clin Pract 2021; 27: 1-10
    CrossrefPubMedGoogle Scholar
  • 29 Weltgesundheitsorganisation. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien. Bern, Göttingen: Hans Huber; 1999
    Google Scholar
  • 30 Wittchen HU, Jacobi F, Rehm J. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacology 2011; 21: 655-679
    CrossrefPubMedGoogle Scholar
  • 31 Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 2010; 17: 94-99
    CrossrefPubMedGoogle Scholar